147 related articles for article (PubMed ID: 38439724)
21. Glioblastoma multiforme in the Muir-Torre syndrome.
Binder ZA; Johnson MW; Joshi A; Hann CL; Griffin CA; Olivi A; Riggins GJ; Gallia GL
Clin Neurol Neurosurg; 2011 Jun; 113(5):411-5. PubMed ID: 21288634
[TBL] [Abstract][Full Text] [Related]
22. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.
Cohen PR; Kurzrock R
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859
[TBL] [Abstract][Full Text] [Related]
23. Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.
Murphy HR; Armstrong R; Cairns D; Greenhalgh KL
Fam Cancer; 2008; 7(3):255-7. PubMed ID: 18236172
[TBL] [Abstract][Full Text] [Related]
24. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
25. First case report of Muir-Torre syndrome associated with non-small cell lung cancer.
Nolan L; Eccles D; Cross E; Crawford G; Beck N; Bateman A; Ottensmeier C
Fam Cancer; 2009; 8(4):359-62. PubMed ID: 19449129
[TBL] [Abstract][Full Text] [Related]
26. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
28. Muir-Torre Syndrome / Turcot Syndrome overlap? A patient with sebaceous carcinoma, colon cancer, and a malignant astrocytoma.
Kleinerman R; Marino J; Loucas E
Dermatol Online J; 2012 May; 18(5):3. PubMed ID: 22630573
[TBL] [Abstract][Full Text] [Related]
29. Muir-Torre Syndrome: A Cutaneous Finding Amidst Broader Malignancies.
Shah RR; Allman P; Schwartz RA
Am J Clin Dermatol; 2023 May; 24(3):375-380. PubMed ID: 36695997
[TBL] [Abstract][Full Text] [Related]
30. Muir-Torre Syndrome in a Middle-Aged Chinese Patient with Sebaceous Carcinoma of the Eyelid.
Wong CY; Tang RK; Lam RF; Io IY; Yuen CY; Ho JW; Tse RK
Semin Ophthalmol; 2015; 30(5-6):420-2. PubMed ID: 24117411
[TBL] [Abstract][Full Text] [Related]
31. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
32. Metachronous occurrence of colorectal cancer in a muir-torre syndrome patient presenting with recurrent sebaceous adenoma of the eyelid: case report and updated review of the literature.
Agiannidis C; Pana ZD; Molyva D; Kalokasidis K; Mixiou M
J Cutan Med Surg; 2012; 16(6):394-9. PubMed ID: 23149194
[TBL] [Abstract][Full Text] [Related]
33. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
34. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
35. Muir-Torre syndrome: a case report and review of the literature.
Okan G; Vural P; Ince Ü; Yazar A; Uras C; Saruç M
Turk J Gastroenterol; 2012 Aug; 23(4):394-8. PubMed ID: 22965514
[TBL] [Abstract][Full Text] [Related]
36. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
37. Sebaceous adenomas of the eyelid and Muir-Torre Syndrome.
Jagan L; Zoroquiain P; Bravo-Filho V; Logan P; Qutub M; Burnier MN
Br J Ophthalmol; 2015 Jul; 99(7):909-13. PubMed ID: 25595178
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
39. MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.
Mahalingam M
Am J Dermatopathol; 2017 Apr; 39(4):239-249. PubMed ID: 28323777
[TBL] [Abstract][Full Text] [Related]
40. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management.
John AM; Schwartz RA
J Am Acad Dermatol; 2016 Mar; 74(3):558-66. PubMed ID: 26892655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
